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Background: Hypomagnesemia is a common adverse event during cetuximab (Cmab) 
treatment. However, few reports have investigated the incidence and risk factors of 
hypomagnesemia in head and neck cancer patients treated with Cmab.
Methods: We retrospectively reviewed 131 head and neck cancer patients who received 
Cmab-containing therapy. Main eligibility criteria were ≥3 Cmab administrations, no prior 
EGFR-directed therapy, and no prophylactic Mg supplementation.
results: Median baseline serum Mg level and number of Cmab administrations were 
2.2 mg/dl and 8, respectively. Overall incidence of hypomagnesemia was 50.4% (grade 
1, 46.6%; grade 2, 3.1%; grade 3, 0%; and grade 4, 0.8%) and differed between patients 
treated with palliative chemotherapy and bioradiation (Cmab and radiation) (63 versus 
24%; P < 0.01). Independent risk factors were low baseline serum Mg [odds ratio (OR) 
161.988, 95% confidence interval (CI) 9.436–2780.895], ≥7 Cmab administrations 
(OR 3.56, 95% CI 1.16–13.98), and concurrent administration of platinum (cisplatin; 
OR 23.695, 95% CI 5.219–107.574, carboplatin; OR 5.487, 95% CI 1.831–16.439). 
Respective incidence of hypomagnesemia in patients in high- (concurrent platinum and 
≥7 Cmab administrations) and low-risk (no concurrent platinum and <7 Cmab adminis-
trations) groups was 66.0 and 6.6% (P < 0.001, OR 28.0).
conclusion: Cmab is associated with a significant risk of hypomagnesemia in patients 
with head and neck cancer with longer term administration and concurrent platinum 
therapy. High-risk patients should be treated with particular care.
Keywords: hypomagnesemia, cetuximab, head and neck cancer, squamous cell carcinoma, chemotherapy, 
radiotherapy
inTrODUcTiOn
Cetuximab (Cmab) is a human–murine monoclonal antibody directed against the EGFR protein 
and is the only approved molecular targeted drug for the treatment of squamous cell carcinoma of 
the head and neck. Cmab has been demonstrated to enhance sensitivity to radiotherapy and chemo-
therapy and improve overall survival (1, 2). As a single agent, Cmab has a response rate of 13% in 
TaBle 1 | Patient and disease characteristics (N = 131).
characteristic
Median age (years) (range) 63 (24–79)
Sex, n (%)
 Male/female 103 (79)/28 (21)
Stage, n (%)
 III/IV 8 (6)/123 (94)
Primary site, n (%)
 Oral cavity 17 (13)
 Oropharynx 26 (20)
 Hypopharynx 32 (24)
 Nasopharynx 21 (16)
 Larynx 11 (8)
 Nasal cavity/paranasal sinus 16 (12)
 Salivary gland 6 (5)
 Unknown primary site 1 (1)
 Others 1 (1)
Initial median Mg level (mg/dl) (range) 2.2 (1.8–2.6)
Initial median adjusted Ca level (mg/dl) (range) 9.4 (7.4–11.4)
Initial median CCra (ml/min) (range) 74.5 (29.7–195.0)
Nutrition risk indexb (range) 104 (66–132)
Platinum history, n (%)
 Yes 48 (37)
 No 83 (63)
CCr, creatinine clearance.
aCockcroft–Gault equation.
b1.519 × serum albumin + 41.7 × actual weight/ideal weight.
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patients with platinum-refractory head and neck squamous cell 
carcinoma (3). This background will likely increase the use of this 
agent and in turn increase the incidence of toxicities associated 
with the prolonged use of Cmab.
The use of anti-EGFR mAbs is associated with a number 
of unique adverse events. Previous meta-analyses have shown 
an increased risk of rash, nail changes, and venous thrombo-
embolism (4–6). Hypomagnesemia associated with Cmab has 
also been reported. Hypomagnesemia can result in cardiac 
arrhythmia, coronary artery vasospasm, and sudden cardiac 
death, and is a serious adverse event in patients treated with 
Cmab. However, the symptoms of hypomagnesemia may be 
fairly non-specific, including irritability, paresthesia, and severe 
fatigue, which are easily attributable to the underlying tumor 
or to previous chemotherapy regimens (7). Thus, the diagnosis 
of Cmab-induced hypomagnesemia may be overlooked, and 
the impact of the condition may be underestimated. Moreover, 
few studies that focused on the incidence and risk factors of 
hypomagnesemia in head and neck cancer patients treated 
with Cmab.
Here, we retrospectively reviewed the incidence and effects 
of hypomagnesemia in a series of head and neck cancer patients 
who received Cmab-containing therapy.
PaTienTs anD MeThODs
We reviewed the medical records of patients treated with Cmab-
containing treatment at the National Cancer Center Hospital East 
Japan between February 2012 and March 2014. Main eligibility 
criteria included age ≥20  years, no prior history of EGFR-
directed therapy, ≥3 Cmab administrations, and no prophylactic 
Mg supplementation and stage III or IV advanced head and neck 
cancer. All patients received Cmab at the dose of 400 mg/m2 IV 
on day 1 and 250  mg/m2 weekly thereafter. In the Cmab plus 
radiation (bioradiation) group, Cmab was given for the duration 
of radiotherapy. Patients treated with palliative chemotherapy 
were eligible to receive a platinum agent (cisplatin, CDDP; or 
carboplatin, CBDCA). In these settings, patients who had at 
least stable disease received Cmab monotherapy until disease 
progression or until unacceptable toxic effects after a maximum 
of six cycles of platinum administration. Serum Mg levels were 
recorded before administration at least once every week during 
the treatment of Cmab. The study was approved by the Clinical 
Research and Ethical Review Board of our institutional hospital 
(task number: 2013-283).
statistical analysis
The incidence of hypomagnesemia was calculated using the 
number of patients with hypomagnesemia and the total number 
of patients receiving Cmab treatment. The primary endpoint was 
the incidence of hypomagnesemia (i.e., Mg concentration below 
the lower limit of normal), and grade was recorded according to 
CTCAE version 4.0. The predictive value for hypomagnesemia 
was assessed by Cox regression models in multivariate analysis, 
with adjustment for the following potential prognostic vari-
ables: baseline serum Mg and calcium level, baseline creatinine 
clearance calculated from the Cockcroft–Gault formula (≥60 
versus <60  ml/min), gender (male versus female), age (<60 
versus ≥60  years), nutrition risk index calculated from serum 
albumin and body weight (8) (≥100 versus <100), number of 
Cmab administrations (<7 versus ≥7), concurrent platinum 
administration (absent versus present), history of platinum 
administration (absent versus present), and grade of rash (0–1 
versus ≥2). SPSS version 21 software (SPSS Inc., Chicago, IL, 
USA) was used for all statistical analyses.
resUlTs
Patient and Treatment characteristics
A total of 131 patient cases were available for analysis. Most 
patients were men (79%) with a median age of 63 years (range 
24–79 years). Main primary disease sites included the hypophar-
ynx (24%) and oropharynx (20%). Eight patients (6%) had stage 
III disease and the remainder (94%) had stage IV. Over half of 
the patients had a history of platinum administration; among 
these, median time from the last administration of platinum to 
the initiation of Cmab was 154  days (range 7–2650). Median 
baseline serum Mg level, serum Ca level, and creatinine clearance 
were 2.2 mg/dl (range 1.8–2.6), 9.4 mg/dl (range 7.4–11.4), and 
74.5 ml/min (range 29.7–195.0), respectively (Table 1). The most 
frequent treatment form was palliative chemotherapy (48%), 
and the median number of cycles of Cmab administration was 8 
(range 3–65) (Table 2).
TaBle 2 | Treatment characteristics (N = 131).
characteristic
Treatment form, n (%)
 Bioradiation 25 (19)
 Induction chemotherapy
 PTX + CBDCA + Cmab 30 (23)
 DTX + CDDP + Cmab 10 (8)
 PTX + Cmab 1 (1)
 CDDP + 5-FU + Cmab 1 (1)
 Palliative chemotherapy
 PTX + CBDCA + Cmab 25 (19)
 Cmab alone 16 (12)
 CDDP + 5-FU + Cmab 16 (12)
 PTX + Cmab 5 (4)
 DTX + Cmab 1 (1)
 CBDCA + 5-FU + Cmab 1 (1)
Median no. of Cmab administrations, n (range) 8 (3–60)
Concurrent platinum (%)
 Yes 83 (63)
 No 48 (37)
PTX, paclitaxel; CBDCA, carboplatin; Cmab, Cetuximab; DTX, docetaxel; CDDP, 
cisplatin; 5-FU, 5-fluorouracil.
FigUre 1 | Time to appearance (left) and the worst degree (right) of hypomagnesemia.
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incidence and risk Factors of 
hypomagnesemia
Almost all patients (96%) had a decrease in serum Mg level 
during treatment compared with baseline measurements. The 
median Mg reduction was 0.4  mg/dl (range 0 to −1.2), which 
was corresponding to 20% (0–67). A higher (≥2.2 mg/dl) baseline 
serum Mg level was associated with a steeper slope (mean reduc-
tion: −0.51 versus −0.39 mg/dl; P = 0.012). The overall incidence 
of hypomagnesemia was 50.4% (grade 1, 46.6%; grade 2, 3.1%; 
grade 3, 0%; and grade 4, 0.8%), with a median follow up of 
76 days (range 20–624). Median time to the onset of hypomagne-
semia was 32 days (range 8–427), and the most severe decrease 
was seen at 55  days (range 10–455) (Figure  1). The incidence 
of hypomagnesemia varied according to treatment form, being 
higher in patients treated with palliative chemotherapy than in 
those treated with bioradiation (63 versus 24%; P < 0.001, Table 3). 
On multivariate analysis, low baseline serum Mg [odds ratio (OR) 
161.988, 95% confidence interval (CI) 9.436–2780.895], ≥7 Cmab 
administrations (OR 3.556, 95% CI 1.16–13.98), and concurrent 
administration of CDDP (OR 23.695, 95% CI 5.219–107.574) or 
CBDCA (OR 5.487, 95% CI 1.831–16.439) were associated with 
hypomagnesemia (Table 4). Respective incidence of hypomagne-
semia in patients in the high- (concurrent platinum and ≥7 Cmab 
administrations) and low-risk (no concurrent platinum and <7 
Cmab administrations) groups was 66.0 and 6.6% (P <  0.001, 
OR 28.0; Table 5), respectively. Serum Ca level, which influences 
serum Mg level, was assessed in all patients at the time of the 
worst hypomagnesemia. The overall incidence of hypocalcemia 
was low (grade 1, 2%; grade 2, 2%), and a statistically significant 
correlation between these decreases during treatment was not 
seen (Spearman’s rho = 0.154, P = 0.104). The most commonly 
observed symptom considered to be related to hypomagnesemia 
was cramps (23%). No mental alteration or seizures were recorded.
status after appearance of 
hypomagnesemia
Among the 66 patients who developed hypomagnesemia, 61 
(94%) continued with Cmab-containing treatment, of whom 
52 received intravenous (IV) Mg supplementation. These 61 
patients with hypomagnesemia received a cumulative total of 533 
Cmab administrations. Intravenous Mg supplementation during 
treatment was given at 16.6 meq/cycle. Thirteen (25%) of the 52 
supplemented patients received oral low-dose Mg sulfate tem-
porarily (median dose 3 g/day). No patient solely discontinued 
Cmab-containing treatment due to intolerable hypomagnesemia 
only. In those patients with hypomagnesemia at the time of Cmab 
discontinuation (n =  49), median time to serum Mg recovery 
FigUre 2 | Time to recovery from hypomagnesemia after stopping 
cmab administration.
TaBle 5 | serum Mg change according to risk classification.
high-risk 
 group n = 66
low-risk 
 group n = 15
P-value Odds 
ratio
cmab cycle ≥7 
and concurrent 
platinum (+)
cmab cycle <7 
and concurrent 
platinum (−)
Median initial Mg 
(range)
2.2 (1.8–2.6) 2.2 (1.8–2.6) – –
ΔMg (mg/dl)c 
(range)
−0.5 (0 to −1.2) −0.3 (0 to −0.8) 0.001a –
ΔMg%d (range) −21 (0 to −67) −13 (0 to −31) 0.001a –
Hypomagnesemiae 44 (66.6%) 1 (6.6%) <0.001b 28.0
aMann–Whitney U test.
bFisher’s exact test.
cMinimum Mg − initial Mg.
dΔMg/initial Mg.
eAll grades.
TaBle 4 | Multivariate analysis of hypomagnesemia.
Variable Odds ratio 95% ci P-value
Initial Mg (mg/dl) 161.988 9.436–2780.895 <0.001
Initial Ca (mg/dl) 0.717 0.293–1.752 0.465
Initial CCr (ml/min) 0.748–8.726 0.134
 ≥60 (n = 104) Referent
 <60 (n = 27) 2.556
Age (year) 0.363–2.295 0.849
 <60 (n = 54) Referent
 ≥60 (n = 77) 0.914
Nutrition risk index 0.623–4.104 0.329
 ≥100 (n = 83) Referent
 <100 (n = 48) 1.599
Cmab cycle, n 1.16–13.98 0.02
 <7 (n = 35) Referent
 ≥7 (n = 96) 3.556
Concurrent CDDP 5.219–107.574  <0.001
 No (n = 104) Referent
 Yes (n = 27) 23.695
Concurrent CBDCA 1.831–16.439 0.002
 No (n = 71) Referent
 Yes (n = 60) 5.487
Platinum history 0.729–5.009 0.188
 No (n = 80) Referent
 Yes (n = 51) 1.911
Rash (grade) 0.468–3.187 0.683
 <2 (n = 89) Referent
 ≥2 (n = 42) 1.221
CCr, creatinine clearance.
TaBle 3 | incidence of hypomagnesemia according to treatment form.
Treatment form n (%)
Bioradiation (n = 25) 6 (24)
Induction chemotherapy (n = 43) 20 (47)
Palliative chemotherapy (n = 63) 40 (63)
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to pretreatment levels was 35  days (range 6–408  days), and all 
patients eventually recovered (Figure  2). Minimum serum Mg 
level during Cmab-containing treatment, concurrent platinum 
administration, and number of Cmab administrations were not 
associated with a longer recovery period (≥35 days).
DiscUssiOn
In this study, we found that Cmab is associated with a significant 
risk of hypomagnesemia in patients with head and neck cancer 
who were receiving concurrent platinum therapy for an extended 
period. Risk varied with treatment form. These findings indicate 
the importance of early monitoring of serum Mg level during 
Cmab-based therapy and suggest that although prophylactic Mg 
supplementation is not necessary, special attention should be 
given to high-risk patients.
In healthy individuals, serum Mg concentrations are tightly 
controlled between intestinal absorption and renal excretion 
and vary between 0.77  mmol/l (1.82  mg/dl) and 1.10  mmol/l 
(2.33 mg/dl) (9). Eighty percent of serum Mg is filtered in the 
glomeruli, with 95% being reabsorbed in the nephron. Patients 
with advanced cancer might develop hypomagnesemia for any of 
several reasons, besides anti-EGFR therapy, including decreased 
oral intake, surgery, platinum agents, and diarrhea (10, 11). 
Hypomagnesemia during anti-EGFR therapy is mainly caused 
by a decrease in Mg reabsorption in the kidney. The Mg channel 
transient receptor potential cation channel, sub-family M, mem-
ber 6 (TRPM6) is involved in the active reabsorption of Mg in the 
limb of the loop of Henle and distal convoluted tubule. Activation 
of renal EGFR located at the basolateral membrane is necessary 
to prevent renal Mg wasting by stimulation of the epithelial Mg 
channel TRPM6 (12, 13). Tejpar et  al. found clear evidence of 
defective renal Mg handling, namely, an inappropriately high 
fractional excretion of Mg in the urine in the setting of serum 
5Enokida et al. Cetuximab-Related Hypomagnesemia in HNC
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hypomagnesemia (14). In our study, almost all patients showed a 
progressive decrease in serum Mg concentration, and the overall 
incidence of hypomagnesemia was comparable with that in a 
previous report, which mainly examined patients with colorectal 
cancer (15). However, the incidence of clinically important grade 
3/4 hypomagnesemia was relatively low (0.8%) in comparison 
with a previously reported meta-analysis, in which grade 3/4 
hypomagnesemia occurred in 4.8–5.6% of patients receiving 
Cmab-based therapy (16, 17). The authors suggested that it might 
be reasonable to start proactive Mg supplement when grade 1 
hypomagnesemia occurred. Patients with higher baseline Mg 
levels tend to have more pronounced Mg wasting, as previously 
reported (14).
Our multivariate analysis to assess potential variables affecting 
the development of hypomagnesemia found that the only base-
line characteristic, which predicted hypomagnesemia was low 
baseline Mg level, irrespective of patient age, baseline creatinine 
clearance, nutrition status, or history of platinum administration. 
Concurrent platinum administration was also detected as a risk 
factor for hypomagnesemia. CDDP directly causes cytotoxic 
damage to the proximal tubule and tubular reabsorption defects, 
resulting in hypomagnesemia (18). In addition, a recent study 
showed that CDDP treatment might also downregulate EGF and 
TRPM6 in the rat kidney, causing renal Mg loss (19). Moreover, 
CDDP itself has been associated with shifts in erythrocyte 
cellular-to-plasma Mg ratios (20). Hypomagnesemia is observed 
in up to 50% of patients treated with CDDP-containing regimens 
(18, 21). Carboplatin nephrotoxicity is similar in nature to CDDP 
nephrotoxicity but occurs less frequently and is usually much less 
severe. Carboplatin also causes tubular damage which leads to 
hypomagnesemia but is often reversible (22). Mild glomerular 
impairment and hypomagnesemia have each been reported in up 
to 25% of children (23–25).
A retrospective study of 114 colorectal cancer patients from 
the Roswell Park Cancer Institute suggested a direct relationship 
between the duration of Cmab exposure and hypomagnesemia 
(26). Tejpar et al. reported similar findings in a prospective study 
of 98 patients treated with EGFR-targeting monoclonal antibod-
ies with or without chemotherapy (14). Both studies showed that 
less than 3 months of Cmab exposure was associated with a lower 
incidence of hypomagnesemia. This finding is important, given 
that many patients with head and neck cancer receive Cmab for 
long periods as maintenance. Together, these findings clearly 
explain the difference in incidence between our present biora-
diation group and palliative group. Generally, patients treated 
with bioradiation receive fewer administrations of Cmab than 
those receiving palliative chemotherapy and without concurrent 
platinum agents.
Although an optimal replacement strategy has yet to be 
determined, Mg replacement should be considered for patients 
with grade 2 hypomagnesemia with risk factors (elderly, cardiac 
disease history) and should be offered to patients with grade 3/4 
hypomagnesemia from the viewpoint of safety (27). Further, 
the biologic relationship between Mg and cancer progression 
is unclear, and there is no definite evidence to suggest that Mg 
supplementation reverses the anti-tumor effects of EGFR inhi-
bition. This suggests that proactive Mg replacement should be 
recommended. In our study, after the appearance of hypomagne-
semia, we successfully continued Cmab administration mainly 
under intravenous Mg supplementation, indicating its effec-
tiveness and tolerance. With respect to supplemental method, 
many patients with metastatic colorectal cancer receiving Cmab 
developed severe and refractory hypomagnesemia and poorly 
tolerated oral Mg supplementation due to diarrhea (28). On the 
other hand, rapid elevation of plasma Mg concentration may 
inhibit Mg reabsorption, leading to hypermagnesiuria (29, 30). 
In addition, one-quarter of our present patients who continued 
Cmab administration after the appearance of hypomagnesemia 
received oral Mg sulfate in combination with intravenous Mg 
supplementation without severe diarrhea. The optimum method 
of Mg supplementation warrants further evaluation. In a previ-
ous study (14), hypomagnesemia was reversible and complete 
recovery was seen once the anti-EGFR targeted agent was 
discontinued. In our present report, serum Mg levels corrected 
within 4–6 weeks of stopping Cmab. A stop-and-go approach to 
Cmab administration is an alternative for patients with severe 
and refractory hypomagnesemia and without a large tumor 
burden. Several retrospective studies have examined the role of 
early hypomagnesemia induced by Cmab as a predictor of effi-
cacy and outcome in colorectal cancer (31, 32). However, the role 
of hypomagnesemia as predictive of outcome in head and neck 
patients treated with Cmab has not been clearly established, and 
we were also unable to assess this because of the heterogeneity of 
patient characteristics and treatment forms.
Several limitations of the study warrant mention. First, due to 
a lack of precise information, we did not evaluate other potential 
variables, such as use of diuretics, diarrhea, or oral intake during 
treatment. As an example, CDDP treatment also produces gastro-
intestinal side effects and requires diuretics, which might lead to 
greater Mg depletion. Second, we did not assess symptoms related 
to hypomagnesemia with a validated questionnaire. This might 
have underestimated the symptomatic impact of Cmab-induced 
hypomagnesemia. Prospective observational studies will provide 
further evidence to guide practice.
cOnclUsiOn
In this study, we showed that Cmab is associated with a significant 
risk of hypomagnesemia in patients with head and neck cancer 
who were receiving longer term administration and concurrent 
platinum therapy. This risk varies with the treatment form. Early 
monitoring of serum Mg level is important when Cmab-based 
therapy is performed, especially in high-risk patients. Evaluation 
of timing, dose, and route of administration of Mg supplementa-
tion, as well as nutritional education, in this population requires 
further study.
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